361 related articles for article (PubMed ID: 25750175)
1. Improvements in progression-free and overall survival due to the use of anti-angiogenic agents in gynecologic cancers.
Schmid BC; Oehler MK
Curr Treat Options Oncol; 2015 Jan; 16(1):318. PubMed ID: 25750175
[TBL] [Abstract][Full Text] [Related]
2. Anti-angiogenesis therapy in gynecologic malignancies.
Liu FW; Cripe J; Tewari KS
Oncology (Williston Park); 2015 May; 29(5):350-60. PubMed ID: 25979545
[TBL] [Abstract][Full Text] [Related]
3. Anti-angiogenic drugs currently in Phase II clinical trials for gynecological cancer treatment.
Wei XW; Zhang ZR; Wei YQ
Expert Opin Investig Drugs; 2013 Sep; 22(9):1181-92. PubMed ID: 23782133
[TBL] [Abstract][Full Text] [Related]
4. The development and use of vascular targeted therapy in ovarian cancer.
Chase DM; Chaplin DJ; Monk BJ
Gynecol Oncol; 2017 May; 145(2):393-406. PubMed ID: 28238563
[TBL] [Abstract][Full Text] [Related]
5. Anti-angiogenic agents in ovarian cancer: past, present, and future.
Monk BJ; Minion LE; Coleman RL
Ann Oncol; 2016 Apr; 27 Suppl 1(Suppl 1):i33-i39. PubMed ID: 27141068
[TBL] [Abstract][Full Text] [Related]
6. An angiogenic tumor phenotype predicts poor prognosis in ovarian cancer.
Wieser V; Tsibulak I; Reimer DU; Zeimet AG; Fiegl H; Hackl H; Marth C
Gynecol Oncol; 2023 Mar; 170():290-299. PubMed ID: 36758419
[TBL] [Abstract][Full Text] [Related]
7. Current role of anti-angiogenic strategies for glioblastoma.
Thomas AA; Omuro A
Curr Treat Options Oncol; 2014 Dec; 15(4):551-66. PubMed ID: 25173555
[TBL] [Abstract][Full Text] [Related]
8. Emerging therapies: angiogenesis inhibitors for ovarian cancer.
Jackson AL; Eisenhauer EL; Herzog TJ
Expert Opin Emerg Drugs; 2015 Jun; 20(2):331-46. PubMed ID: 26001052
[TBL] [Abstract][Full Text] [Related]
9. Weekly ixabepilone with or without biweekly bevacizumab in the treatment of recurrent or persistent uterine and ovarian/primary peritoneal/fallopian tube cancers: A retrospective review.
Roque DM; Ratner ES; Silasi DA; Azodi M; Rutherford TJ; Schwartz PE; Nelson WK; Santin AD
Gynecol Oncol; 2015 Jun; 137(3):392-400. PubMed ID: 25792179
[TBL] [Abstract][Full Text] [Related]
10. [Gynecologic cancer].
Sugiyama T; Takeuchi S; Fukagawa T
Gan To Kagaku Ryoho; 2014 Feb; 41(2):157-61. PubMed ID: 24743194
[TBL] [Abstract][Full Text] [Related]
11. Beyond Bevacizumab: An Outlook to New Anti-Angiogenics for the Treatment of Ovarian Cancer.
Mahner S; Woelber L; Mueller V; Witzel I; Prieske K; Grimm D; Keller-V Amsberg G; Trillsch F
Front Oncol; 2015; 5():211. PubMed ID: 26500886
[TBL] [Abstract][Full Text] [Related]
12. [Anti-angiogenic treatments in metastatic colorectal cancer: Does a continuous angiogenic blockade make sense?].
Jary M; Borg C; Bouché O; Kim S; André T; Bennouna J
Bull Cancer; 2015 Sep; 102(9):758-71. PubMed ID: 26232849
[TBL] [Abstract][Full Text] [Related]
13. Novel anti-angiogenic therapies for malignant gliomas.
Norden AD; Drappatz J; Wen PY
Lancet Neurol; 2008 Dec; 7(12):1152-60. PubMed ID: 19007739
[TBL] [Abstract][Full Text] [Related]
14. Proangiogenic tumor proteins as potential predictive or prognostic biomarkers for bevacizumab therapy in metastatic colorectal cancer.
Bruhn MA; Townsend AR; Khoon Lee C; Shivasami A; Price TJ; Wrin J; Arentz G; Tebbutt NC; Hocking C; Cunningham D; Hardingham JE;
Int J Cancer; 2014 Aug; 135(3):731-41. PubMed ID: 24374727
[TBL] [Abstract][Full Text] [Related]
15. Pazopanib in ovarian cancer.
McLachlan J; Banerjee S
Expert Rev Anticancer Ther; 2015; 15(9):995-1005. PubMed ID: 26296187
[TBL] [Abstract][Full Text] [Related]
16. Antiangiogenic agents in gynecological cancer: State of art and perspectives of clinical research.
Gadducci A; Lanfredini N; Sergiampietri C
Crit Rev Oncol Hematol; 2015 Oct; 96(1):113-28. PubMed ID: 26126494
[TBL] [Abstract][Full Text] [Related]
17. The role of Cediranib in ovarian cancer.
Orbegoso C; Marquina G; George A; Banerjee S
Expert Opin Pharmacother; 2017 Oct; 18(15):1637-1648. PubMed ID: 28933580
[TBL] [Abstract][Full Text] [Related]
18. The prognostic significance of anti-angiogenesis therapy in ovarian cancer: a meta-analysis.
Li J; Li S; Chen R; Yu H; Lu X
J Ovarian Res; 2015 Aug; 8():54. PubMed ID: 26242216
[TBL] [Abstract][Full Text] [Related]
19. Current knowledge and open issues regarding bevacizumab in gynaecological neoplasms.
Bellati F; Napoletano C; Gasparri ML; Ruscito I; Marchetti C; Pignata S; Tomao F; Benedetti Panici P; Nuti M
Crit Rev Oncol Hematol; 2012 Jul; 83(1):35-46. PubMed ID: 22056314
[TBL] [Abstract][Full Text] [Related]
20. Bevacizumab for the treatment of cervical cancer.
Bizzarri N; Ghirardi V; Alessandri F; Venturini PL; Valenzano Menada M; Rundle S; Leone Roberti Maggiore U; Ferrero S
Expert Opin Biol Ther; 2016; 16(3):407-19. PubMed ID: 26796332
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
